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A gut pathobiont synergizes 
with the microbiota to instigate 
inflammatory disease marked by 
immunoreactivity against other 
symbionts but not itself
João Carlos Gomes-Neto1, Hatem Kittana1, Sara Mantz1, Rafael R. Segura Munoz1,  
Robert J. Schmaltz1, Laure B. Bindels  1, Jennifer Clarke1,5, Jesse M. Hostetter2,  
Andrew K. Benson1, Jens Walter3,4 & Amanda E. Ramer-Tait  1
Inflammatory bowel diseases (IBD) are likely driven by aberrant immune responses directed against 
the resident microbiota. Although IBD is commonly associated with a dysbiotic microbiota enriched 
in putative pathobionts, the etiological agents of IBD remain unknown. Using a pathobiont-induced 
intestinal inflammation model and a defined bacterial community, we provide new insights into the 
immune-microbiota interactions during disease. In this model system, the pathobiont Helicobacter 
bilis instigates disease following sub-pathological dextran sulfate sodium treatment. We show that 
H. bilis causes mild inflammation in mono-associated mice, but severe disease in the presence of a 
microbiota, demonstrating synergy between the pathobiont and microbiota in exacerbating pathology. 
Remarkably, inflammation depends on the presence of H. bilis, but is marked by a predominant Th17 
response against specific members of the microbiota and not the pathobiont, even upon the removal 
of the most immune-dominant taxa. Neither increases in pathobiont burden nor unique changes in 
immune-targeted microbiota member abundances are observed during disease. Collectively, our 
findings demonstrate that a pathobiont instigates inflammation without being the primary target of a 
Th17 response or by altering the microbiota community structure. Moreover, our findings point toward 
monitoring pathobiont-induced changes in microbiota immune targeting as a new concept in IBD 
diagnotics.
IBD is associated with an altered gut microbiota composition (i.e., dysbiosis) characterized by a loss of mem-
bers belonging to the Firmicutes and Bacteroidetes phyla and an expansion of Proteobacteria1. Although 
cause-and-effect-relationships for disease-related dysbioses have not been established2–4, the microbiota asso-
ciated with IBD has been hypothesized to be enriched in pathobionts—microorganisms that are thought to 
exert a pathological role when their relationship with the host is altered5,6. Unlike frank pathogens, pathobionts 
presumably live symbiotic lifestyles under normal circumstances without negatively affecting host health; how-
ever, they are capable of selectively expanding during episodes of inflammation and may exacerbate the disease 
process7,8. It is believed that pathobionts can instigate and/or perpetuate pro-inflammatory responses; however, 
the exact immune-microbiota interactions governing pathobiont-mediated intestinal pathology are not well 
understood9–17.
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Figure 1. Colonization with the pathobiont Helicobacter bilis induced severe intestinal inflammation in the 
presence of a microbiota but did not alter microbiota composition. (A) Gross cecal scores depicting disease 
severity for Conventional (Conv) and Altered Schaedler Flora (ASF) mice colonized with or without the 
pathobiont H. bilis (Hb) for 3 wks and then either treated with 1.5% DSS or left untreated (n = 7–22 animals 
per treatment). (B) H. bilis abundance in cecal contents from Conv and ASF mice colonized with Hb for 3 
wks and then treated with or without DSS (n = 7–10 animals per treatment). (C) ASF bacterial abundances in 
cecal contents of ASF-bearing animals colonized with Hb and either treated with 1.5% DSS or left untreated 
at 11–12 wks of age (n = 10–12 animals per treatment). (D) Principal Component Analysis (PCA) of the ASF 
community structure for mice from all treatments. The PCA plot dots represent the entire ASF community 
based on abundance of each organism as measured by species-specific qPCR assays in cecal contents (n = 10–12 
animals per treatment). The red arrows in the PCA plot depict the directionality and magnitude of each ASF 
member’s contribution to the variability across both PC1 and PC2. (E) Histopathological disease scores for 
cecal tissues from germ-free (GF), ASF-bearing, H. bilis mono-associated and H. bilis colonized ASF-bearing 
mice either treated with 1.5% DSS or left untreated. The letter n in the graph indicates the number of mice 
used per treatment group. Scores were based on presence or absence of morphological alterations such as 
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Here, we explore these inter-relationships using a mouse model harboring the Altered Schaedler Flora (ASF) 
in which disease can be induced through the addition of the pathobiont Helicobacter bilis and a sub-pathological 
dose of dextran sulfate sodium (DSS)18. Although H. bilis and other enterohepatic Helicobacters are well-known 
for contributing to intestinal inflammation in immunocompromised or inflamed hosts18–23, the role of particular 
microbiota members in mediating pathology has not been elucidated due to the difficulty in determining spe-
cific immune-microbiome interactions in conventional animals. By using the defined ASF community in both 
wild-type and Rag1−/− mice, we systematically identified (i) the relative contribution of the pathobiont and the 
microbiota to disease severity, (ii) to what degree disease was associated with changes in the microbial commu-
nity composition, (iii) the role of the adaptive immune system in disease, (iv) the specific microbes towards which 
immune responses were directed and (v) the contributions of immune-targeted taxa to the disease process.
Results
Pathobiont colonization can induce an equivalent degree of disease in mice with a conven-
tional or defined microbiota. To study specific immune-microbe interactions in pathobiont-mediated 
colitis, we first established that a mouse model with a defined microbial community can replicate the severity 
of pathobiont-induced intestinal inflammation observed in the same mouse line harboring a conventional (e.g., 
complex and undefined) microbiota. To this end, C3H/HeN adult mice (8–10 weeks old) carrying either a con-
ventional (Conv) microbiota or the ASF community from birth were colonized with H. bilis for three weeks 
prior to treatment with a sub-pathological dose of DSS (1.5%). Disease severity was not significantly different 
between Conv and ASF mice (Fig. 1A), and no differences in H. bilis abundance were observed across treatments 
(Fig. 1B). In addition, H. bilis-DSS-mediated inflammation did not result in major alterations to the abundances 
of individual bacteria or the community structure in ASF mice, except for decreased numbers of ASF 492, which 
was decreased in all mice treated with DSS (Fig. 1C and D). Homogeneity of variances analysis (Betadisper) using 
Bray-Curtis dissimilarity coefficients further confirmed the absence of differences in ASF community dispersion 
across treatments (P = 0.573) as did results from PERMANOVA (R2 = 21.28, P = 0.003) and ANOSIM (R = 0.133) 
analyses, which found only minor treatment effects. Because H. bilis colonization exacerbated disease equiva-
lently in both Conv and ASF microbiota mice following DSS treatment, this defined model now permits the study 
of exact immune-microbe interactions during disease.
The resident microbiota acts synergistically with the pathobiont to induce severe disease. 
Having established that the pathobiont plus the ASF community are sufficient to cause disease following low-dose 
DSS treatment, we next determined the relative contributions of the resident microbiota and pathobiont to the 
pathology. Groups of adult germ-free and ASF-bearing C3H/HeN mice were colonized with or without H. bilis 
for three weeks and then either treated with low-dose DSS or left untreated. Histopathological evaluation of cecal 
tissues revealed that ASF-bearing mice colonized with H. bilis and treated with DSS developed severe intestinal 
lesions characterized by stromal collapse and epithelial ulceration, increased inflammatory infiltrate, submu-
cosal edema and gland hyperplasia (Fig. 1E and G; Fig. S1A). In contrast, only moderate lesions were observed 
in mice mono-associated with H. bilis and treated with DSS. Of note, histopathological analysis demonstrated 
that germ-free and ASF control mice treated with 1.5% DSS developed only mild microscopic lesions, confirm-
ing that this low dose itself is sub-pathological (Fig. 1E) as previously reported18. Enumeration of H. bilis by 
qPCR revealed no significant effects of the ASF community and/or DSS treatment on pathobiont abundance 
(Fig. 1F). Thus, even though H. bilis by itself induces moderate disease following a low-dose of DSS, the pres-
ence of the ASF community is necessary for severe disease, indicating that the resident microbiota exacerbates 
pathobiont-mediated inflammation.
The pathobiont and resident microbiota synergistically induce a pro-inflammatory response 
associated with disease. Analysis of cytokine profiles from the cecal tissues of H. bilis-ASF-DSS mice 
showed that severe intestinal inflammation is marked by a significant increase in the production of sev-
eral cytokines considered hallmarks of a Th17 response. This response included elevation of TGF-ß1 and the 
pro-inflammatory cytokines IL-1ß, IL-17A and IL-17F (Fig. 2A–D) as well as a corresponding decrease in pro-
duction of the anti-inflammatory cytokine IL-10 (Fig. 2E) as compared to either H. bilis-DSS or ASF-DSS mice. 
IL-33 and IFN-γ production were also increased in the inflamed ceca of H. bilis-ASF-DSS mice (Fig. S1B and C). 
stromal collapse or ulceration, gland hyperplasia, inflammatory cell infiltrate in the lamina propria and 
submucosal edema across groups. (F) Pathobiont abundance measured by qPCR in cecal contents of mono-
associated or ASF-bearing mice treated with DSS or left untreated (n = 10–12 animals per treatment, each 
represented by an individual circle). (G) Representative photomicrographs of hematoxylin-eosin (H & E) 
stained tissues were taken at 100X magnification. Images were selected based on two criteria: (1) representing 
the mean histopathological score for each group and (2) by considering the pathologist’s description of the 
morphological changes. Horizontal bars represent group means in all graphs. (C) Differing superscript letters 
indicate significant differences across treatments as per a non-parametric Kruskal-Wallis one-way ANOVA, 
followed by a post-hoc test (Dunn’s test, P < 0.05). (A,B and E,F) Asterisks refer to the degree of significance for 
differences as determined by a non-parametric unpaired Mann-Whitney test using a two-tailed distribution for 
P-value calculations (*P < 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 and NS = not significant at P ≥ 0.05). 
No comparisons in Fig. 1F were significant (P ≥ 0.05). Only significant differences between treatments are 
presented in the graphs with the exception of one comparison in Fig. 1A. Pathobiont and ASF bacterial 
abundances were measured using species-specific qPCR assays. Experiments were performed using male and 
female C3H/HeN mice at 8-10 wks of age; mice were colonized with H. bilis for 3 wks.
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Production of TNF-α and IL-22 was elevated in H. bilis-ASF versus H. bilis mono-associated mice, but DSS 
treatment did not further increase the secretion of either cytokine (Fig. S1D and E). Evaluation of immune cell 
populations via flow cytometry revealed an expansion of effector memory (EM) CD44high CD62Llow CD4+ T cells 
Figure 2. The resident microbiota acted synergistically with the pathobiont to induce a pro-inflammatory immune 
response. (A–E) Pro- and anti-inflammatory cytokines present in cecal explants from germ-free (GF), ASF-bearing, 
H. bilis mono-associated and H. bilis colonized ASF bearing mice treated with 1.5% DSS or left untreated (n = 9–12 
animals per treatment). (F) Proportion of effector memory (EM) CD44highCD62Llow CD4+ T cells in mesenteric 
lymph nodes (each dot represents a pool of 2–3 animals) of ASF-bearing mice colonized with or without H. bilis and 
either treated with DSS or left untreated. (A–F) Horizontal bars represent treatment means in all graphs. Asterisks 
depict the degree of significance for differences as determined by a non-parametric unpaired Mann-Whitney test 
using a two-tailed distribution for P-value calculations (*P < 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001). 
Only significant differences between treatments are presented in the graphs. Experiments were performed using 
male and female C3H/HeN mice at 8-10 wks of age; mice were colonized with H. bilis for 3 wks.
www.nature.com/scientificreports/
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Figure 3. The absence of adaptive immunity limited the severity of pathobiont-induced intestinal inflammation 
and the magnitude of the Th17 response without altering microbiota composition. (A) Gross cecal scores 
depicting disease in ASF-bearing C57BL/6 wild type (WT) and Rag1−/− mice harboring the ASF and 
colonized with or without H. bilis (Hb) and either treated with 2% DSS or left untreated (n = 10-18 animals 
per treatment). (B) Pathobiont abundance in cecal contents as measured by species-specific qPCR (n = 9-16 
animals per treatment). (C,D) IL-1ß (C) and IL-17 (D) concentrations in cecal explants (n = 10-18 animals 
per treatment). (E–H) Total numbers of effector memory (EM) CD44high CD62Llow CD4+ T cells (E) and total 
IL-17A+ CD4+ T cells (F) in mesenteric lymph nodes (MLN; n = 15–18 animals per treatment). (G,H) ASF 
bacterial abundances in cecal contents of ASF-bearing C57BL/6 WT and Rag1−/− mice harboring the ASF 
and colonized with or without H. bilis and either treated with 2% DSS or left untreated (n = 9-18 animals per 
treatment). (A–F) Horizontal bars represent treatment means in all graphs. Differences in the absolute immune 
cell counts were tested using an unpaired parametric T-test. A non-parametric unpaired Mann-Whitney test 
was used to evaluate the gross cecal scores, pathobiont abundance and cytokine concentrations. All P-values 
were calculated, across all tests, using a two-tailed distribution. Asterisks show the degree of significance for 
the indicated comparisons in each graph (*P < 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001). Only 
www.nature.com/scientificreports/
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(Fig. 2F) in H. bilis-ASF-DSS mice compared to either ASF-DSS or H. bilis-ASF mice. Together, the Th17 signa-
ture observed in the pro-inflammatory cytokine profile and the expansion of activated CD4+ T cells imply a con-
tributing role for adaptive immunity in precipitating severe intestinal inflammation and pathology in this model.
The adaptive immune system is required for severe pathobiont-mediated intestinal inflam-
mation. To assess the role of the adaptive immune response in pathobiont mediated-disease, we switched 
our mouse model to the C57BL/6 background to compare disease severity for the H. bilis-ASF-DSS treatment in 
isogenic wild-type (WT) and Rag1−/− mice, the latter of which lack mature T and B cells. In this genetic back-
ground, WT H. bilis-ASF-DSS mice develop disease that is equivalent in severity to that observed in the C3H/HeN 
line. In contrast, Rag1−/− H. bilis-ASF-DSS mice experienced significantly less severe disease compared to their 
WT counterparts, confirming a pathological role for the adaptive immune system in pathobiont-mediated disease 
(Fig. 3A). Pathobiont abundance was not significantly altered by adaptive immune status alone (Fig. 3B). The 
Rag1−/–dependent reduction in disease was characterized by a marked decrease in local cytokine and chemok-
ine production, including IL-1ß and IL-17 (Fig. 3C and D) as well as G-CSF, MIP-2 and IL-6 (Fig. S2A–C). In 
contrast, GM-CSF, MCP-1, IL-1α, IL-33 and IFN-γ were not affected by the Rag1 deletion and remained high 
in both WT and Rag1−/− H. bilis-ASF-DSS mice (Fig. S2D and H). The severe disease observed in WT C57BL/6 
H. bilis-ASF-DSS mice was accompanied by a significant expansion of both EM CD4+ T cells and Th17 cells 
(Fig. 3E and F and Fig. S3A). Increased populations of activated B cells and iTregs (CD25+ Foxp3+ Neuropilin-
1low Helioslow CD4+) were also observed in WT C57BL/6 mice with pathobiont-induced disease (Fig. S3B and 
C). Total numbers of IFN-γ+ CD4+ T cells, IL-17A+ IFN-γ+ CD4+ T cells, Tregs (CD25+ Foxp3+ CD4+), nTregs 
(CD25+ Foxp3+ Neuropilin-1high Helioshigh CD4+) and CD8b+ T cells remained unaltered (Fig. S3D–J).
Analysis of ASF bacterial abundances in the C57BL/6 mouse line showed no major differences between either 
WT or Rag1−/− mice colonized with H. bilis and treated with DSS (Fig. 3G and H). As observed in our previous 
experiments, DSS treatment significantly decreased the abundance of ASF 492 (E. plexicaudatum) independently 
of pathobiont status. The absence of significant changes in microbiota structure were further confirmed using 
Betadisper (P = 0.098 and P = 0.17 for WT and Rag1−/−, respectively), ANOSIM (R statistics = 0.1331 and 0.1224 
for WT and Rag1−/−, respectively) and PERMANOVA (nearly 15% of both WT and Rag1−/− dataset variances 
were explained by treatments) analyses.
Pathobiont colonization triggers CD4+ Th17 cell immunoreactivity against specific members 
of the resident microbiota, but not toward itself. Our finding that severe H. bilis-mediated disease 
requires a microbiota and is associated with IL-17 production led us to next determine which of the pathobi-
ont and defined ASF bacterial community members are the actual targets of this Th17 responses. CD4+ T cells 
were isolated from the mesenteric lymph nodes of either germ-free or ASF-bearing C3H/HeN mice with or 
without H. bilis colonization for three weeks prior to low-dose DSS treatment as described in Fig. 1E. Cytokine 
profiles were then assessed in supernatants of these CD4+ T cells after co-culturing with mitomycin C-treated 
naïve splenocytes pulsed with antigens derived from either H. bilis or individual ASF members or with unpulsed 
splenocytes. Cytokine production was considered specific to a certain ASF member if there were significant 
increases over (i) unstimulated T cells isolated from the same mice, (ii) antigen-stimulated T cells harvested 
from equivalently-treated mice not harboring the ASF community and (iii) antigen-stimulated T cells from 
ASF-bearing mice treated with DSS but not colonized with H. bilis.
CD4+ T cells isolated from severely diseased H. bilis-ASF-DSS mice produced significantly elevated lev-
els of IL-17A when stimulated with antigens from either ASF 356, ASF 361 and, to a lesser extent, ASF 502 as 
compared to H. bilis mono-associated-DSS mice (Fig. 4A,B,E and F; Fig. S4D). Antigen-specific responses to 
ASF 360, 492, 500 and 519 were negligible (Fig. S4A–C and E) and those to 457 were undetectable (Fig. 4C). 
Interestingly, IL-17A immunoreactivity specifically against the H. bilis pathobiont itself was not observed 
(Fig. 4D). Importantly, qPCR analysis of cecal tissues and contents showed no correlation between the abun-
dances of the pathobiont and species primarily targeted by the immune system (i.e., ASF 356 and ASF 361) during 
disease (Fig. S4F–H).
Similar to IL-17A, the same patterns of immunoreactivity to ASF 356 and 361, but not the pathobiont, were 
also observed for IL-17F (Fig. S5A–I). Antigen-specific IL-22 production from CD4+ T cells harvested from H. 
bilis-ASF-DSS mice was observed upon stimulation with antigens from ASF 356 but not following stimulation 
with H. bilis antigens (Fig. S6A–I). Although ASF antigen-specific IFN-γ and IL-10 responses were observed, 
they were not unique to the severely diseased H. bilis-ASF-DSS mice (Figs S7A–I and S8A–I). Given the require-
ment of both the pathobiont and ASF microbiota for severe disease, the pattern of immunoreactivity targeting 
immune-dominant ASF members but not H. bilis demonstrates that this pathobiont can elicit Th17 immune 
responses against the resident microbiota and bring about intestinal inflammation without being the primary 
immunological target.
Removing immune-dominant gut symbionts redirects the Th17 immune response to other ASF 
members and does not alter the severity of pathobiont-mediated disease. To determine the role 
of the immune-dominant members ASF 356 and ASF 361 in pathobiont-induced disease, we next compared 
significant differences between treatments are presented in the graphs. (G,H) Differing superscript letters 
indicate significant differences across treatments as per a non-parametric Kruskal-Wallis one-way ANOVA, 
followed by a post-hoc test (Dunn’s test, P < 0.05). ASF bacterial abundances were measured using species-
specific qPCR assays. Experiments were performed using male and female WT or Rag1−/− C57BL/6 mice at 
8-10 wks of age; mice were colonized with H. bilis for 3 wks.
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disease susceptibility in H. bilis colonized and DSS-treated mice harboring either a complete ASF community 
or ASF communities lacking immune dominant strains (Fig. 5A). Specifically, prior to low-dose DSS exposure, 
we colonized germ-free mice with either (i) H. bilis plus all eight ASF members, (ii) H. bilis plus the ASF with-
out 356 (the major immune-dominant member), (iii) H. bilis plus the ASF without 356 and 361 (the two most 
immune-dominant members), and (iv) H. bilis plus the ASF without 457 (an ASF member that is not immune 
targeted). Surprisingly, removal of the immune-dominant ASF members 356 and/or 361 did not limit disease 
severity (Fig. 5B), and the pathobiont abundance remained unaltered (Fig. 5C). Interestingly, ASF 361 became 
Figure 4. Pathobiont colonization triggered CD4+ Th17 cell immunoreactivity against specific members of 
the resident microbiota but not toward itself. (A,B) IL-17A secretion from CD4+ T cells isolated from the 
mesenteric lymph nodes of germ-free (GF), ASF-bearing, H. bilis mono-associated and H. bilis colonized 
ASF bearing mice treated with 1.5% DSS or left untreated. CD4+ T cells were either left unstimulated (NS) or 
stimulated with whole-cell sonicate antigens from either ASF 356 (Clostridium sp.) (A), ASF 361 (Lactobacillus 
murinus) (B), ASF 457 (Mucispirillum schaedleri) (C) or the pathobiont (H. bilis) (D) for 72 hrs. (E,F) IL-17A 
secretion from CD4+ T cells isolated from the mesenteric lymph nodes of either H. bilis mono-associated 
mice (E) or ASF-bearing mice colonized with H. bilis (F) and stimulated with whole-cell sonicate antigens 
from each of the individual ASF members or H. bilis (n = 4–5 pools of 2–3 animals per pool per treatment). 
Pairwise comparisons in (E) and (F) were performed with respect to unstimulated cells. Box-and-whiskers plot 
depict minimum and maximum values in addition to the median (i.e., horizontal bar in the middle). (A–D) 
Horizontal bars represent treatment means in all graphs. (A–F) Asterisks depict the degree of significance for 
differences as determined by a non-parametric unpaired Mann-Whitney test using a two-tailed distribution for 
P-value calculations (*P < 0.05, **P ≤ 0.01, *** P ≤ 0.001, ****P ≤ 0.0001 and NS = not significant P ≥ 0.05). 
Experiments were performed using male and female C3H/HeN mice at 8-10 wks of age; mice were colonized 
with H. bilis for 3 wks.
www.nature.com/scientificreports/
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Figure 5. Removal of immune-dominant gut symbionts did not alter the severity of pathobiont-mediated disease 
and precipitated a shift in the pattern of Th17 immunoreactivity. (A) Experimental design describing all treatment 
groups which included all ASF members or ASF communities devoid of the following taxa: ASF 356 (Clostridium sp.), 
ASF 356 and 361 (Lactobacillus murinus), or ASF 457 (Mucispirillum schaedleri). Mice harboring these communities 
were then colonized with H. bilis for 3 wks and then either treated with 1.5% DSS or left untreated at 12–13 wks of 
age. (B) Gross cecal scores depicting disease severity (n = 10–28 animals per treatment). (C) H. bilis abundance in 
cecal contents as measured by species-specific qPCR (n = 7–10 animals per treatment). (D-H) IL-17A secretion from 
CD4+ T cells isolated from the mesenteric lymph nodes of mice in all treatments except for those colonized with the 
ASF minus 457. CD4+ T cells were either left unstimulated (NS) or stimulated with whole-cell sonicate antigens from 
either ASF 356 (Clostridium sp.) (D), ASF 361 (L. murinus) (E), ASF 502 (Clostridium sp.) (F), ASF 457 (M. schaedleri) 
(G) or the pathobiont (H. bilis) (H) for 72 hrs (n = 3-10 pools of 2–3 animals per pool per treatment). (B–H) Asterisks 
depict the degree of significance for differences as determined by a non-parametric unpaired Mann-Whitney test 
using a two-tailed distribution for P-value calculations (*P < 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001 and 
NS = not significant P ≥ 0.05). (B–H) Differing superscript letters indicate significant differences across treatments 
as per a non-parametric Kruskal-Wallis one-way ANOVA, followed by a post-hoc test (Dunn’s test, P < 0.05). 
Experiments were initiated when male and female C3H/HeN mice were 4–5 wks of age.
www.nature.com/scientificreports/
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Figure 6. Removal of immune-dominant gut symbionts did not create patterns of microbial community structure 
that were unique to pathobiont-induced disease. (A–H) ASF bacterial abundances in cecal contents of animals 
colonized with all ASF members or devoid of the following taxa: ASF 356 (Clostridium sp.), 356 and 361 (Lactobacillus 
murinus), or 457 (Mucispirillum schaedleri). Mice harboring these communities were then colonized with H. 
bilis for 3 wks and then either treated with 1.5% DSS or left untreated at 12–13 wks of age (n = 10–11 animals per 
treatment). Asterisks depict the degree of significance for differences as determined by a non-parametric unpaired 
Mann-Whitney test using a two-tailed distribution for P-value calculations (*P < 0.05, **P ≤ 0.01, ***P ≤ 0.001, 
****P ≤ 0.0001 and NS = not significant P ≥ 0.05). Differing superscript letters indicate significant differences across 
treatments as per a non-parametric Kruskal-Wallis one-way ANOVA, followed by a post-hoc test (Dunn’s test, 
P < 0.05). ND refers to not detectable. ASF bacterial abundances were measured using species-specific qPCR assays. 
Experiments were initiated when male and female C3H/HeN mice were 4–5 wks of age.
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the primary target of the Th17 response in the absence of ASF 356 (Fig. 5D–F). Similarly, when both ASF 356 and 
361 were not present, ASF 502 became the immune dominant symbiont with other members also being targeted, 
albeit to lesser degree (Fig. 5D–F; Fig. S9A–L). Also notable was the observation that even in these communities of 
lower complexity, Th17 immunoreactivity against both ASF 457 and H. bilis remained negligible (Fig. 5G and H; 
Fig. S9H and M).
Some changes in individual ASF member abundances were observed following removal of the 
immune-dominant species, including increased numbers of ASF 360 (Fig. 6B), an expansion of ASF 361 upon 
removal of ASF 356 or ASF 457 (Fig. 6C and D), and, as seen in our previous experiments, decreased numbers 
of ASF 492 following DSS treatment regardless of the community composition (Fig. 6E). However, no patterns 
of microbial community structure were observed that were unique to pathobiont-induced disease. Of note, 
the immune-dominant ASF members targeted by the Th17 response were not enriched in the IgA+ fraction 
of cecal contents during disease (Fig. S10A–K). Collectively, these findings demonstrate that removal of the 
immune-dominant gut symbiont(s) during pathobiont-mediated inflammation maintains pathobiont-mediated 
Th17 immune responses against remaining members and not the pathobiont itself without affecting the disease 
severity.
Discussion
IBD is hypothesized to result from aberrant immune responses directed against gut symbionts, which can be initi-
ated by the loss of intestinal barrier integrity24–26. These chronic diseases are routinely characterized by microbial 
dysbiosis, including overrepresentation of the phylum Proteobacteria3,4,27–29. Certain Proteobacteria are thought 
to behave as pathobionts during IBD, and much like the different virulence strategies found among frank path-
ogens belonging to this phylum, multiple strategies seem to have evolved in pathobionts that enable them to 
contribute to disease. These general strategies include altering barrier function, invading the gut epithelium, 
and/or stimulating local inflammatory responses, but the mechanisms through which these strategies manifest 
are not well known5,6. To define specific mechanisms that underlie general pathobiont strategies, we focused on 
the pathobiont H. bilis, which is capable of triggering inflammatory disease in immunocompromised rodent 
models18,20–23,30. In this  current model of immunosufficient, gnotobiotic mice colonized with H. bilis, a subpatho-
logical perturbation of the intestinal barrier (DSS treatment) is required for disease, but is not sufficient because 
severe pathology also requires a microbiota. Using a simplified microbiota (ASF), we show that H. bilis precip-
itates severe disease without significant increases in its own abundance and without substantial changes in gut 
microbial community structure. These features differentiate the pathobiont characteristics of H. bilis from other 
pathobionts such as the Adherent and Invasive Escherichia coli strain LF82 (AIEC LF82), which elicits chronic 
colitis and brings about changes in microbiota composition after disruption of innate immune signaling11,31.
Perhaps the most striking characteristic of the severe intestinal inflammation observed in ASF mice colo-
nized with H. bilis and exposed to low-dose DSS is the requirement for a microbiota. The microbiota need not 
be complex, as severe disease was detected in mice with a conventional community and in those harboring the 
simplified ASF consortium. Involvement of the microbiota in pathobiont-initiated disease has also been observed 
during H. hepaticus-driven colitis32,33 as well as during the induction of disease in immunocompromised hosts by 
the pathobionts P. mirabilis and K. pneumoniae9,10,34. Collectively, these studies and our own observations for H. 
bilis highlight the fact that multiple species of pathobiont act synergistically with resident symbionts to exacer-
bate pathology. It is important to note that the requirement of a microbiota for disease initiation and/or severity 
is not unique to pathobiont-mediated pathology. Indeed, the magnitude of intestinal inflammation in several 
genetically-induced immunodeficient mouse models (IL-10−/−, IL-2−/−, TCR-alpha−/−)35–39 also depends on one 
or more members of the microbiota. Thus, the microbiota can play synergistic roles in disease processes that are 
initiated by entirely different mechanisms (pathobiont-mediated or genetic predisposition), suggesting that its 
involvement may be a general feature of inflammatory intestinal diseases.
One of the most fundamental ways in which the resident microbiota can contribute to chronic intestinal 
inflammation is via aberrant engagement of the adaptive immune system40. In our model, we demonstrate that 
pathobiont-induced tissue damage is mediated, in part, by the adaptive immune system and characterized by 
Th17 responses toward gut symbionts. These observations are consistent with those made by Belkaid and col-
leagues, who show that microbiota-specific T cells are activated during acute gastrointestinal infection with 
Toxoplasma gondii and are functionally identical to pathogen-specific T cells, leading the authors to conclude that 
primary immune responses to intestinal pathogens likely occur in the context of secondary immune responses 
directed against the microbiota41,42. The individual microbial targets of such T cell responses during disease are 
largely unknown, with the exception of flagellin39,43–48. Much of the difficulty in dissecting contributions of patho-
bionts, specific T cell responses, and the microbiota during inflammatory intestinal disease lies in the complexity 
of the microbiota itself9. We circumvented this problem by using a defined microbiota mouse model, in which 
H. bilis colonization and low-dose DSS treatment caused a disease phenotype indistinguishable from that of 
mice carrying a complex microbiota. With this reductionist approach, we were able to demonstrate that spe-
cific resident gut symbionts—primarily ASF 356 (Clostridium sp.), ASF 361 (Lactobacillus murinus) and ASF 
502 (Clostridium sp.)—are the dominant targets of a Th17 response rather than the pathobiont itself. However, 
these Th17 targeted species are not selectively coated with IgA during disease as has been demonstrated in other 
models of intestinal inflammation49. The discordance we observed between Th17 and IgA immune reactivity 
may indicate that differential immune signatures could occur in IBD. Future studies will investigate how H. bilis 
instigates Th17 responses exclusively against the microbiota as well as define the exact contribution of Th17 cells 
to pathobiont-mediated disease. Considering that some Helicobacter species were recently reported to precipitate 
antigen-specific T cell responses against themselves but not other bacterial taxa that expanded during disease, 
additional work to provide perspective regarding the diversity of immunological influence exerted by various 
Helicobacter species is warranted50.
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The ability of H. bilis to incite CD4+ T cell responses against the microbiota, but not itself, is a novel finding 
that may partly explain why no single microorganism or immune response against particular microbiota mem-
bers has ever been associated with inflammatory bowel diseases. Even more striking is our observation that severe 
pathobiont-mediated intestinal inflammation does not appear to depend on any specific member of the micro-
biota, as removal of the immune-dominant taxa in the ASF community altered the primary targets, but did not 
influence disease severity. We believe this finding is not only of mechanistic significance, but also of great impor-
tance to IBD diagnostics, because it implies that testing for changes in the development of immune responses to 
the gut microbiota may be of far greater diagnostic value than testing for responses to a specific pathobiont or 
particular member of the microbiota.
Materials and Methods
Bacterial strains. Helicobacter bilis WiWa18,51 was grown in broth overlaid onto Brucella agar plates. Agar 
consisted of Brucella broth (BD BBL™ Brucella Broth, DifcoTM Becton Dickinson, Sparks, MD) and 0.125% 
activated charcoal (Acros Organics, Thermo Fisher Scientific Inc., Fair Lawn, NJ) adjusted to pH 5 using 6 M 
HCl solution prior to the addition of 1.6% bacteriological agar (Amresco®, Solon, OH). After autoclaving, cooled 
agar was with supplemented with 20% heat-inactivated newborn calf serum (hi-NCS; HyClone®, Thermo Fisher 
Scientific Inc.) and 2% Vitox supplement (Oxoid™, Thermo Fisher Scientific Inc.) prior to pouring plates. The 
broth overlay consisted of 70% Brucella broth (autoclaved and cooled prior to use), 12% urea (BD BBL™ Urea 
Agar Base, DifcoTM Becton Dickinson), 17% hi-NCS and 1% isovitalex supplement (BBL™ Medium Enrichment 
for Fastidious Microorganisms, BD). H. bilis cultures were maintained in modular incubator chambers (Billups-
Rothenberg, Del Mar, CA) under microaerophilic conditions (80% N2, 10% H2 and 10% CO2) at 37 °C. The broth 
overlay was changed every 12 hr for 36 hr prior to harvesting H. bilis for inoculation. All cultures were contin-
uously checked for aerobic contaminants via plating on Tryptic Soy Agar plates (BD Tryptic Soy Agar, DifcoTM 
Becton Dickinson) at 37 °C. Prior to inoculation, H. bilis cultures were evaluated for purity, morphology and 
motility via dark-phase microscopy. Bacteria were then suspended in Brucella broth (BD BBL™ Brucella Broth, 
DifcoTM Becton Dickinson) at an approximate concentration of 108 CFU/mL using MacFarland standards.
The ASF microbial community consisted of ASF 356, Clostridium sp.; ASF 360, Lactobacillus intestinalis; ASF 
361, Lactobacillus murinus; ASF 457, Mucispirillum schaedleri; ASF 492, Eubacterium plexicaudatum; ASF 500, 
Pseudoflavonifractor sp.; ASF 502, Clostridium sp.; and ASF 519, Parabacteroides goldsteinii52,53. Individual ASF 
members were cultured under anaerobic conditions as previously described54. ASF strains, H. bilis WiWa, and 
founder C3H/HeN gnotobiotic breeding mice harboring all eight ASF members were kind gifts from Dr. Michael 
Wannemuehler, Iowa State University.
Animal experiments. Conventional (Conv) and ASF-bearing C3H/HeN mice, ASF-bearing C57BL/6 or 
Rag1−/− mice, germ-free (GF) C3H/HeN, and GF Rag1−/− mice were bred and maintained at the University 
of Nebraska-Lincoln Gnotobiotic Mouse Facility. All GF and ASF-bearing mice were bred and reared under 
gnotobiotic conditions in flexible film isolators. All mice were fed an autoclaved chow diet ad libitum (LabDiet 
5K67, Purina Foods). Germ-free status was routinely checked as previously described54. Conventional mice 
were housed in autoclaved cages on a positive pressure, individually ventilated caging system (Allentown Inc., 
Allentown, NJ), maintained on autoclaved bedding, provided autoclaved water and fed an autoclaved diet. Cages 
were only opened in a biosafety cabinet. ASF-bearing mice used in experiments were colonized with the ASF via 
vertical transmission (i.e., from birth). ASF colonization status of breeding and experimental mice was verified 
using fecal samples and previously published qPCR assays54. Mice inoculated with H. bilis received a single oral 
gavage containing 108 CFU/mL in 200 μL. H. bilis colonization was verified 7–10 days post-inoculation using fecal 
samples and a qPCR assay. All control Conv and ASF-bearing animals were confirmed to be devoid of H. bilis.
Defined microbial communities consisting of various ASF members were assembled in adult germ-free C3H/
HeN mice by first resuspending pure cultures of each individual ASF member to a density of 106–108 CFU/mL 
using McFarland standards. Mice received a 200 uL oral gavage of each organism daily for three consecutive days. 
Community assembly was achieved by first introducing ASF 360 (L. intestinalis) and 519 (P. goldsteinii); remain-
ing ASF members were then added in the following order: ASF 500 (Pseudoflavonifractor sp.), 502 (Clostridium 
sp.), 492 (E. plexicaudatum), 356 (Clostridium sp.), 361 (L. murinus), and 457 (M. schaedleri).
To trigger disease, mice were provided with either 1.5% (for all C3H/HeN) or 2% (all C57BL/6 WT and 
Rag1−/−) dextran sulfate sodium salt (DSS; MW = 36,000–50,000, MP Biomedicals, LLC, Solon, OH) in their 
drinking water for 5 days, followed by a restitution period with regular water for 4 days prior to necropsy. 
Age-matched control animals received regular drinking water for the duration of the study. Considering previ-
ously published data18, each experiment measuring disease phenotype as well as immunological and bacteriolog-
ical parameters consisted of at least 6–8 animals per treatment and each experiment was performed once or twice. 
In some experiments, sample size was adjusted to maximize statistical power as the data for most parameters 
measured were not normally distributed and cell samples needed to be pooled for select assays. Animals were 
not randomly distributed across treatments. All experimental procedures were performed in accordance with the 
Guide for the Care and Use of Laboratory Animals (Eighth Edition, National Academy of Sciences). All proce-
dures involving animals were approved by the Institutional Animal Care and Use Committee at the University of 
Nebraska-Lincoln (Protocols 817 and 1215).
DNA isolation and quantitative real-time PCR. DNA was isolated from feces and cecal contents as pre-
viously described using a phenol-chloroform-isoamyl alcohol and chloroform-isoamyl alcohol based protocol55. 
Cecal tissue DNA was isolated using the QIAamp DNA Blood and Tissue Kit as per manufacturer instruc-
tions (QIAamp DNA Blood and Tissue Kit, Qiagen®, Germantown, MD). DNA was quantified using 
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fluorescent molecule labeling, and all samples were diluted to a final concentration of 10 ng/µL prior to using 
1 µL of the DNA template in each qPCR reaction as previously described54. Quantification of all ASF members 
in wet cecal contents and tissues was performed using previously described qPCR assays. The abundance of 
H. bilis was quantified using a newly designed primer set and qPCR assay54. Primer sequences were Forward: 
5′ TGGCTTGCCAGAGCTTGA 3′ and Reverse: 5′ CTGCTAGCAACTAAGGACG 3′ (IDT DNA Technologies, 
Coralville, IA). Amplicon size was 111 base pairs. Thermocycling conditions included: (i) an initial denaturation 
step of 10 min at 95 °C; (ii) 35 cycles of 20 s at 95 °C, 30 s at 60 °C (annealing temperature), and 45 s at 68 °C; (iii) 
one cycle of 20 s at 95 °C; (iv) one cycle of 30 s at 60 °C; (v) one 20 min interval to generate a melting curve; and 
(vi) one cycle of 45 s at 95 °C. Both forward and reverse primers were used at a final concentration of 300 nM. See 
Supplementary Information for more detailed information.
Gross and histopathological lesion scores. At necropsy, a gross cecal disease score was assigned using 
a previously described set of criteria56 modified to include atrophy, emptying, enlargement of the cecal tonsil, 
presence of mucoid contents, and presence of intraluminal blood. For each parameter, a score of 0 (absent) or 
1 (present) was given. Final scores were additive for all parameters; the higher the final gross score, the greater 
the disease severity. The investigator assigning gross scores was not blinded to treatments; however, tissues from 
healthy control mice were always scored first to establish baseline values. To assess microscopic lesions, the apical 
portions of cecal tissues were collected, fixed in 10% neutral buffered formalin (Thermo Fisher Scientific Inc.) 
and subsequently processed, sectioned and stained with hematoxylin and eosin (H&E). Tissues were scored by 
a board-certified veterinary pathologist (J.M.H.) who was blinded to treatments. Cumulative histopathological 
scores ranged from 0–30 and were based on a 0 to 5 score for each of the following parameters adapted from a 
previous report56: gland hyperplasia, stromal collapse, edema, cellular inflammation, ulceration and mucosal 
height. Higher cumulative scores represented more severe disease.
Cecal explant cultures. Cultures of cecal fragments were prepared as previously described for colon frag-
ments37. More detailed information can be found in the Supplementary Material.
CD4+ T cell stimulation. A culture system was adapted from a previously described protocol57 as a method 
to provide purified CD4+ T cells with an in vitro stimulation to assess antigen-specific cytokine production in 
response to H. bilis or individual ASF antigens. See Supplementary Information for more detailed information.
Cytokine quantification. Chemokine and cytokine levels (i.e., from cecal explants or CD4+ T cell superna-
tants) were measured using customized Mouse Cytokine/Chemokine Magnetic Bead Kits (Milliplex, Millipore, 
Billerica, MA) and a MAGPIX instrument (Luminex Corporation, Austin, TX), except for TGF-ß1, which was 
measured using a Mouse TGF-ß1 ELISA Ready-SET-Go (eBioscience Inc.) as per manufacturer instructions.
Flow cytometry. Immune cell phenotypes were assessed as previously described58,59. See Supplementary 
Information for more detailed information and schematics of gating strategies (Fig. S11A–E and S12A–F).
Immunoglobulin A (IgA)-based bacterial cell sorting and quantification. This method was adapted 
from a previously published work49. A detailed description of the protocol used for bacterial cell sorting and 
quantification can be found in the Supplementary Material.
Statistical analysis. Statistical analyses were performed using GraphPad Prism 7 (version 7.0a, 2016, 
GraphPad Software, Inc., La Jolla, CA) and the R software, version 3.3.1 (R Core Team 2016, R Foundation 
for Statistical Computing, Vienna, Austria). More detailed description of all analyses can be found in the 
Supplementary Information. Significant differences between two treatments are presented by * = P < 0.05, 
** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001 and NS = not significant at P ≥ 0.05.
Data availability. R scripts and raw data for the ecological analysis (i.e., ASF community structure and cor-
relation analysis) are accessible at https://github.com/jcgneto/HbilisASFmodel.
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